Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

IV-PCA

PreclinicalSmall molecule

NNang Kuang Pharmaceutical Co., Ltd.

IV-PCA is one of 2 small molecule programs targeting Hypokalemia. It is currently in Preclinical.

1

Indications

3

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypokalemiaActive, not recruiting

HypokalemiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Hypokalemia

#DrugCompanyPhaseTrials

Klor-Con

IV-PCA

NNang Kuang Pharmaceutical Co., Ltd.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypokalemia1 trial

Hypokalemia and Intravenous Patient Controlled Analgesia

Completed·SSeoul Medical Center·N/A·NCT01269099·50 enrolled

Postoperative Ileus1 trial

Thoracic Epidural for Postoperative Ileus

Completed·SSamsung Medical Center·N/A·NCT02491385·28 enrolled

Unspecified1 trial

A Phase I Dose-escalation Study of a Single Administration of Extended-Release Injectable Suspension (ND-340)

Suspended·NNang Kuang Pharmaceutical Co., Ltd.·Phase 1·NCT04515953·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for IV-PCA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IV-PCA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IV-PCA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nang Kuang Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNang Kuang Pharmaceutical Co., Ltd.

Related News